Evidence map›Paper›PMID 41620483›Full record

ArticleScientific reports2026

Evaluating the prognostic significance of HIST1H4C in breast cancer: implications for neoadjuvant therapy.

Li Qian, Rui Ge, Zhong Haihu, Zhu Cairong, Cai Yuanxuan, Liao Yongdong, Zhu Xiaofeng, Li Jingjing, Ye Xuan, Chen Kai and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Li Qian *Thyroid and Breast Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Rui Ge *Huadong Hospital Affiliated to Fudan University, Shanghai, China.
Zhong Haihu *Thyroid and Breast Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Zhu CairongThyroid and Breast Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Cai YuanxuanThyroid and Breast Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Liao YongdongThyroid and Breast Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Zhu XiaofengThyroid and Breast Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Li JingjingThyroid and Breast Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Ye XuanThyroid and Breast Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Chen KaiGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. Ckaichen@126.com.
Li JieThyroid and Breast Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China. lijie2958@gwcmc.org.

Funding

Foundation of Guangzhou Women and Children's Medical Center 2021BS023Foundation of Guangzhou Women and Children's Medical Center 2023BS036Guangzhou Science and Technology, Basic and Applied Basic Research Topic 2024A04J4987National Natural Science Foundation of China 82102791National Natural Science Foundation of China 82172917National Natural Science Foundation of China 82201522National Natural Science Foundation of China 82203112National Natural Science Foundation of China 82271650
6 · The paper itself

Abstract

Breast cancer is a common and highly malignant, currently, HIST1H4C was found to be associated with several human malignancies. The purpose of this study is to investigate tissue HIST1H4C expression in breast cancer and explore its role in disease progression and its interaction with neoadjuvant therapy efficacy. we analyzed tissue HIST1H4C mRNA expression in BC tissue samples from 105 patients received with neoadjuvant therapy using qPCR between 2019 and 2022. Statistical analysis showed that a high expression of HIST1H4C before neoadjuvant therapy was positively related to good responder (CR + PR), while high expression of HIST1H4C after neoadjuvant therapy was negatively related good responder. And HIST1H4C expression was significantly decreased in patients with good responder. In addition, high HIST1H4C expression was also related to ER negative, PR negative, high KI67 expression, high level of histological grade, large tumor size and more lymph node metastases in Curtis database. Furthermore, high HIST1H4C expression before and after-treatment in our center or in database has a positively correlation with poor prognosis. HIST1H4C is the potential biomarker of neoadjuvant therapy and prognosis for breast cancer.

Indexed as

Biomarkers, TumorBreast NeoplasmsNeoadjuvant TherapyAdultFemaleGene Expression Regulation, NeoplasticHumansLymphatic MetastasisMiddle AgedPrognosisBiomarkers, TumorBCHIST1H4CNeoadjuvant therapy efficacyPrognosis

Identifiers

PMID41620483
PMCPMC12917089

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.